Related by context. All words. (Click for frequent words.) 82 metastatic castrate resistant 78 metastatic hormone refractory 78 prostate cancer CRPC 76 dasatinib Sprycel ® 74 castrate resistant prostate cancer 74 erlotinib Tarceva ® 74 metastatic androgen independent 74 sorafenib Nexavar 74 prostate cancer mCRPC 74 trastuzumab Herceptin R 74 mapatumumab 73 resistant hormone refractory 73 Aflibercept 73 irinotecan doxorubicin oxaliplatin paclitaxel 73 irinotecan containing 73 hormone refractory metastatic prostate 73 5 FU leucovorin 73 evaluating tivozanib 73 interferon gamma 1b 73 HER2 positive metastatic breast 73 lintuzumab SGN 72 bevacizumab Avastin ® 72 refractory chronic lymphocytic 72 PEGylated Fab fragment 72 Hormone Refractory Prostate Cancer 72 pegylated liposomal doxorubicin 72 TO AVOID PREGNANCY WHILE 72 prostate cancer HRPC 72 FEMALES SHOULD BE ADVISED 72 alvespimycin 72 oral ridaforolimus 72 plus prednisone 72 AVASTIN 72 recurrent NSCLC 72 virus HCV protease inhibitor 72 sorafenib tablets 72 cetuximab Erbitux ® 72 standard chemotherapy regimen 71 Meets Primary Endpoint 71 cetuximab Erbitux R 71 Combination REOLYSIN R 71 FOLFOX6 chemotherapy regimen 71 gemcitabine Gemzar 71 recurrent glioblastoma multiforme 71 cetuximab Erbitux 71 metastatic renal cell carcinoma 71 FOLFOX6 71 Tezampanel 71 CYT# potent vascular disrupting 71 ELACYT 71 MAGE A3 ASCI 71 relapsed MM 71 leukemia AML 71 castration resistant prostate cancer 71 Randomized Phase 71 evaluating picoplatin 71 PEGINTRON TM 70 alfa 2a 70 Tarceva TM 70 docetaxel chemotherapy 70 bevacizumab Avastin R 70 Nexavar sorafenib 70 FUSILEV enhances 70 PROVENGE sipuleucel T 70 stage IIIB 70 Phase 2b Clinical Trial 70 mRCC 70 estramustine 70 imatinib Gleevec ® 70 Phase #b/#a clinical 70 sunitinib Sutent ® 70 pertuzumab 70 unresectable stage 70 Oral Fingolimod 70 SPRYCEL ® 70 Romidepsin 70 R lenalidomide 70 axitinib 70 FOLFIRI 70 cell lymphoma CTCL 70 pegylated interferon alfa 2a 70 unresectable tumors 70 systemic anaplastic large 70 pan HDAC inhibitor 70 PROSTVAC VF 70 HGS ETR2 70 Myelodysplastic Syndrome MDS 70 Doxil ® 70 nilotinib Tasigna ® 70 Peginterferon alfa 2b 70 advanced metastatic renal 70 metaglidasen 70 metastatic pancreatic 70 5 fluorouracil leucovorin 70 Cutaneous T 69 anthracycline taxane 69 beta 1a 69 novel VDA molecule 69 hyperplasia BPH 69 phase IIb clinical 69 infusional 5-FU/LV 69 metastatic malignant 69 Albuferon TM 69 dasatinib Sprycel 69 gemcitabine chemotherapy 69 FOLFOX4 69 lexidronam injection 69 androgen independent 69 gefitinib Iressa 69 Cloretazine ® 69 CTAP# Capsules 69 Neoadjuvant 69 Temsirolimus 69 docetaxel Taxotere ® 69 Fulvestrant 69 mCRC patients 69 YONDELIS 69 abiraterone acetate 69 temsirolimus 69 metastatic colorectal 69 HGS ETR1 mapatumumab 69 ritonavir boosted 69 ® lenalidomide 69 INCB# [001] 69 stage IIIb IV 69 ribavirin RBV 69 lenalidomide Revlimid R 69 elotuzumab 69 familial amyloidotic polyneuropathy FAP 69 Prostate AdenoCarcinoma Treatment 69 bevacizumab Avastin 69 Phase IIb Trial 69 Erlotinib 69 Ophena TM 69 indolent follicular non 69 sunitinib malate 69 oral prodrug 69 prostate cancer AIPC 69 interferon beta 1a infertility 69 Annamycin 69 Nexavar ® 69 advanced metastatic prostate 69 induced macular edema 69 FOLOTYN ® 69 asymptomatic metastatic 69 HGS ETR1 69 Phase IIIb clinical 69 capecitabine Xeloda 68 AAG geldanamycin analog 68 PNP inhibitor 68 ACTEMRA TM 68 goserelin 68 paclitaxel Taxol ® 68 metastatic GIST 68 Xeloda ® 68 paclitaxel Taxol R 68 PEGylated interferon beta 1a 68 Personalized Immunotherapy 68 cisplatin gemcitabine 68 Intravenous CP 68 Pemetrexed 68 oral nucleoside analogue 68 docetaxel Taxotere R 68 metastatic renal cell 68 Adjuvant Treatment 68 Chronic Hepatitis C 68 forodesine 68 CBLC# 68 II Clinical Trial 68 primary hypercholesterolemia 68 Brentuximab Vedotin SGN 68 thalidomide Thalomid 68 chemotherapy cisplatin 68 Patients Treated With 68 CD3 monoclonal antibody 68 assessing T DM1 68 sunitinib Sutent 68 Elotuzumab 68 radiation sensitizer 68 By JENNIFER LEARN 68 mitoxantrone plus 68 Study Evaluating 68 relapsed multiple myeloma 68 demonstrated antitumor activity 68 Cloretazine 68 orally administered inhibitor 68 Asentar 68 Irinotecan 68 paclitaxel Taxol 68 Ixempra 68 dacarbazine DTIC 68 K ras mutations 68 Vidaza ® 68 Genasense ® oblimersen 68 CIMZIA TM certolizumab pegol 68 pan histone deacetylase 68 Refractory Hodgkin Lymphoma 68 Glufosfamide 68 adalimumab Humira 68 oral deforolimus 68 Safinamide 68 Trial Evaluating 68 LENALIDOMIDE 68 dacarbazine 68 Traficet EN 68 LHRH receptor positive 68 docetaxel Taxotere 68 Relapsed Refractory 68 telaprevir dosed 68 MyVax R 68 neratinib 68 dependent kinase inhibitor 68 Lenalidomide 68 dextromethorphan quinidine 68 Camptosar ® irinotecan 68 Epratuzumab 68 TNF Tumor Necrosis Factor 68 BCG refractory carcinoma 68 antibody MAb 68 R sorafenib tablets 68 cyclophosphamide methotrexate 68 Completes Patient Enrollment 68 gastrointestinal stromal tumors GIST 68 Randomized Phase II 68 HBeAg negative 68 essential thrombocythemia ET 68 CR# vcMMAE 68 VELCADE melphalan 68 PROVENGE ® 68 Metastatic Prostate Cancer 68 SinuNase TM 67 INSPIRE Trial Phase III 67 Phase 2b Trial 67 evaluating satraplatin 67 MKC# MT 67 GW# [003] 67 OvaRex ® MAb 67 IMA# 67 cell carcinoma RCC 67 phase IIb study 67 Velcade bortezomib 67 R roscovitine CDK cyclin 67 relapsed ovarian cancer 67 CCX# B 67 catheter occlusion 67 Antitumor Activity 67 Camptosar ® 67 leukemia CLL 67 adecatumumab 67 lapatinib Tykerb 67 Advanced Renal Cell 67 R Saizen R 67 Novel Oral 67 Pivotal Phase 67 luteinizing hormone releasing 67 CEQ# 67 Bezielle 67 Sprycel dasatinib 67 Azacitidine 67 Flu Cy 67 following fluoropyrimidine oxaliplatin 67 BRIM3 67 Phase #/#a trial 67 Femara letrozole 67 SUPPRELIN R LA 67 IMiDs ® 67 Relapsed Multiple Myeloma 67 R# #mg BID 67 vidofludimus 67 relapsed refractory multiple myeloma 67 Clinical Trial Results 67 Acute Myeloid Leukemia AML 67 custirsen 67 Hsp# Inhibitor 67 itraconazole Sporanox 67 severe hypercholesterolemia 67 Folfox 67 LymphoStat B belimumab 67 EFAPROXYN 67 Chronic Myeloid Leukemia 67 Navelbine ® 67 oral picoplatin 67 bortezomib Velcade R 67 Syncria R 67 ocular formulation 67 PEGylated anti 67 Complicated Skin 67 INCB# [003] 67 generation Hsp# inhibitor 67 galiximab 67 VEGFR2 inhibitor 67 Bosutinib 67 oxaliplatin Eloxatin 67 hormone refractory prostate cancer 67 myelodysplastic myeloproliferative diseases 67 carcinoma mCRC 67 orally inhaled migraine 67 Taxotere chemotherapy 67 Campath alemtuzumab 67 Fludarabine 67 novel nucleoside analog 67 taxane resistant 67 Initiate Phase 67 Previously Treated 67 erlotinib Tarceva 67 vinca alkaloid 67 Ranolazine 67 BRIM2 67 Daclizumab 67 olaparib 67 IL# PE#QQR 67 cancer mCRC 67 sipuleucel T 67 iniparib 67 modified glutathione analog 67 clinically localized prostate 67 sarcoma melanoma 67 non resectable metastatic 67 DU #b 67 plus dexamethasone 67 Advanced Melanoma 67 registrational Phase 67 Ozarelix 67 doxorubicin HCl liposome injection 67 ZYBRESTAT 67 Natalizumab 67 gastrointestinal stromal tumor GIST 67 Newly Diagnosed Multiple Myeloma 67 ongoing Phase 1b 67 Panzem R 67 sapropterin dihydrochloride 67 gemcitabine Gemzar ® 67 fallopian tube carcinoma 67 Romiplostim 67 low dose cytarabine 67 IgG1 monoclonal antibody 67 non splenectomized 67 plus gemcitabine 67 Epothilone D 67 tocilizumab 67 zanolimumab 67 Randomized Double blind 66 PD LID 66 refractory multiple myeloma 66 Omacetaxine 66 5 Fluorouracil 66 cutaneous T 66 Paraplatin ® 66 5-fluorouracil/leucovorin 66 LymphoStat B TM 66 Xeloda capecitabine 66 anthracycline containing 66 Taxotere ® 66 antiretroviral naïve 66 relapsed ALL 66 lymphoid malignancies 66 Relapsed Refractory Multiple Myeloma 66 Bevacizumab 66 Laquinimod 66 Fludara ® 66 phase IIb trial 66 adriamycin 66 Pharmacokinetics PK 66 abacavir lamivudine 66 Severe Sepsis 66 Phase 1b clinical trials 66 Gemzar ® 66 Torisel 66 Controlled Trial 66 Phase Ib II 66 oral rivaroxaban 66 ZOLINZA 66 minimally symptomatic metastatic castrate 66 compound INCB# 66 pomalidomide 66 Phase 2a Trial 66 Castration Resistant Prostate Cancer 66 radiation chemoradiation 66 nucleoside analog 66 AEG# 66 huC# DM4 66 Dose Ranging Study 66 refractory acute myeloid 66 IMPACT IMmunotherapy 66 Dendreon investigational 66 Phase 2a Clinical Trial 66 PREZISTA r 66 Peginterferon 66 Sanofi Aventis Taxotere 66 imatinib Gleevec 66 GOUT 66 temsirolimus Torisel 66 recurrent metastatic ovarian cancer 66 Mg Usa 66 cyclophosphamide FC 66 castration resistant hormone refractory 66 metastatic HRPC 66 IRX 2 66 remission induction 66 Sapacitabine 66 J Am Coll 66 Panzem R NCD 66 Prolongs Survival 66 TELINTRA 66 recurrent metastatic 66 recurrent glioblastoma 66 Vandetanib 66 TTF Therapy 66 Herceptin trastuzumab 66 oropharyngeal candidiasis OPC 66 investigational immunotherapy 66 infliximab monotherapy 66 Amrubicin 66 Diabetic Macular Edema 66 cabazitaxel 66 oral antidiabetic medication 66 recurrent GBM 66 non nucleoside inhibitor 66 neuropathy sparing 66 imatinib mesylate 66 clodronate 66 AVOREN 66 lintuzumab 66 alpha 2a 66 cyclophosphamide chemotherapy 66 paclitaxel carboplatin 66 Pralatrexate 66 Pooled Analysis 66 Trastuzumab 66 Voreloxin 66 Xelox 66 fosbretabulin 66 PEG SN# 66 situ CIS 66 pharmacokinetic PK study 66 Monotherapy 66 cardiometabolic diseases Glucophage 66 Metastatic Colorectal Cancer 66 chronic eosinophilic leukemia 66 Previously Untreated 66 Philadelphia Chromosome Positive 66 Vicriviroc 66 REVLIMID R 66 ALN HPN 66 TBC# 66 Jevtana 66 refractory cutaneous T 66 delivers fluocinolone acetonide FA 66 trastuzumab Herceptin 66 alkylating agent 66 chemosensitizer 66 phase III isavuconazole 66 mTOR inhibitor 66 trastuzumab Herceptin ® 66 Tanespimycin 66 Platinol ® 66 EGFR TKI 66 entinostat 66 evaluating Actimmune 66 metastatic RCC 66 CD# CEA 66 receptor tyrosine kinase inhibitor 66 humanised monoclonal antibody 66 refractory AML 66 non squamous 66 refractory gout 66 CLINICAL DATA 66 Dasatinib 66 paclitaxel cisplatin 66 Androxal TM 66 Quinamed 66 PSMA ADC 66 interferon alfa 2a 66 Avastin bevacizumab 66 potent CYP#A# inhibitors 66 TRANSFORMS 66 Phase 2b Study 66 sorafenib Nexavar ® 66 generation purine nucleoside 66 neoadjuvant 66 PANVAC VF 66 Phase III Trial 66 IN PATIENTS WITH 66 unresectable Stage III 66 FDA APPROVES 66 Ovitrelle R Serostim 66 fluvastatin 66 Tipranavir 66 NATRECOR ® 66 atypical Hemolytic Uremic Syndrome 66 advanced carcinoid 66 vinca alkaloids 66 lymphoma CTCL 66 RhuDex TM 66 gemcitabine carboplatin 66 rosuvastatin #mg 66 Initiates Clinical Trial 66 bone marrow reticulin deposition 66 interferon alfa 66 vandetanib 66 Zorbtive TM 66 Adjuvant Therapy 66 HMG CoA reductase inhibitors 66 plus prednisone prednisolone 66 Phase Ib study 66 PRT# 66 trabectedin 66 vincristine doxorubicin 66 Torisel temsirolimus 66 teriflunomide 66 Heterozygous Familial Hypercholesterolemia 66 thetreatment 66 ALN PCS 66 mycophenolate mofetil 66 davunetide intranasal AL 66 PKC# 66 candesartan cilexetil 66 HCV SPRINT 66 Pegylated Interferon 66 multi kinase inhibitor 66 KRAS mutations occur 66 chemotherapy FOLFOX 66 dihydrochloride Tablets 66 Phase 1b trial 66 non metastatic osteosarcoma 66 investigational monoclonal antibody 65 XL# anticancer compounds 65 selective modulator 65 2 methoxyestradiol 65 FASLODEX 65 adjuvant radiotherapy 65 ixabepilone 65 locoregional recurrence 65 octreotide implant 65 HRPC 65 liposomal formulation 65 TKB# 65 PRTX 65 decitabine 65 docetaxel prednisone 65 BENLYSTA TM 65 lenalidomide dexamethasone 65 MEK Inhibitor 65 Phase Ib clinical trials 65 Treatment Naïve 65 severe renal impairment 65 Lupus Nephritis 65 Atypical Hemolytic Uremic Syndrome 65 azacitidine 65 relapsing remitting MS RRMS 65 AEGR 65 metastatic gastric 65 Solazed TM 65 ara C 65 Lenocta 65 trastuzumab DM1 T DM1 65 R metformin Concor 65 refractory metastatic 65 brand ciclesonide HFA 65 hyperphenylalaninemia HPA due 65 relapsed leukemia 65 Degarelix 65 formerly LymphoStat B 65 flutamide 65 invasive candidiasis 65 phase IIa clinical 65 Cerebril TM 65 tenofovir emtricitabine 65 cediranib 65 Pirfenidone 65 Elagolix 65 XELOX 65 Metastatic Melanoma 65 tumors GIST 65 castrate resistant 65 Cimzia TM 65 baminercept 65 imatinib resistant 65 inhibitor RG# 65 idarubicin 65 AVONEX ® 65 cutaneous T cell 65 bladder ovarian 65 abatacept Orencia 65 Sandostatin R 65 Onrigin 65 esophageal candidiasis 65 investigational oral inhibitor 65 Pivotal Phase III 65 Pegasys ® 65 Anti VEGF 65 ARIMIDEX 65 gemcitabine Gemzar R 65 posaconazole 65 ThermoDox R 65 Pegloticase 65 metastatic CRPC 65 carbamazepine phenobarbital phenytoin rifampin 65 lumiliximab 65 unresectable locally advanced 65 Renal Cell Carcinoma 65 vorinostat 65 Vidaza R 65 oral Xeloda 65 Advanced Solid Tumors 65 efaproxiral 65 protease inhibitor PI 65 KRAS wild 65 GVAX Immunotherapy 65 unique alkylating agent 65 trastuzumab DM1 65 CIMZIA ™ 65 standard chemotherapy regimens 65 samarium Sm 65 worsening thrombocytopenia 65 Telik logo TELINTRA 65 Adjuvant Chemotherapy 65 RhuDex R 65 tesmilifene 65 pralatrexate injection folate analogue 65 ASCO GI 65 TAXOTERE R 65 Anthracycline 65 pegylated interferon alpha 65 Investigational Treatment 65 registrational trial 65 Non Alcoholic Steatohepatitis 65 psoriasis rheumatoid arthritis 65 XL# SAR# 65 Metastatic Renal Cell Carcinoma 65 dimebon latrepirdine 65 postmenopausal osteoporotic women 65 BARACLUDE ® 65 oblimersen 65 deCODE ProstateCancer TM 65 Clolar ® 65 5-FU/LV 65 Melphalan 65 Achieves Primary Endpoint 65 folinic acid 65 elacytarabine 65 undergone radical prostatectomy 65 hydroxymethyl coenzyme 65 metastatic colorectal carcinoma 65 Thiarabine 65 Vitaxin 65 PDX pralatrexate 65 receiving prophylactic anticoagulation 65 carboplatin chemotherapy 65 EGFR expressing mCRC 65 oral chemotherapeutic agent 65 Ophena 65 Platinol ® cisplatin 65 Capecitabine 65 FOLFIRI chemotherapy 65 Vidaza azacitidine 65 Capesaris 65 plus dacarbazine 65 ularitide 65 lomitapide 65 Bayer Nexavar 65 adecatumumab MT# 65 Nilotinib 65 paclitaxel eluting stents 65 Archexin 65 erlotinib Tarceva R 65 BRAF inhibitor 65 Telaprevir VX 65 Mitoxantrone 65 Phase IIb Clinical Trial 65 nab paclitaxel 65 DOXIL 65 tanespimycin 65 peginterferon alfa 2a Pegasys 65 investigational antiplatelet agent 65 ACAPODENE 65 cilengitide 65 dose escalation clinical 65 complement inhibitor eculizumab 65 8mg/kg 65 Myeloma Patients 65 pediatric malignancies 65 Gleevec imatinib mesylate 65 bendamustine 65 vapreotide acetate 65 naïve HCV 65 Phase Ib Clinical Trial 65 Begins Dosing 65 Revlimid lenalidomide 65 mertansine 65 AVODART 65 5 fluorouracil 65 MGd 65 REVLIMID lenalidomide 65 Initiates Enrollment 65 stage IIIB IV 65 relapsing remitting multiple sclerosis 65 Gefitinib 65 NOX E# 65 occlusion PAO 65 Phase III Clinical Trial 65 Cannabinor 65 phase IIa 65 Peginterferon Alfa 2a 65 generation radiolabeled antibody 65 Targretin 65 developing Bicifadine serotonin 65 herpetic keratitis 65 BCIRG 65 Alocrest 64 CoFactor 64 brain metastases originating 64 imatinib therapy 64 Phase III Pivotal 64 velafermin 64 Tarceva erlotinib 64 rasagiline tablets 64 Pyridorin 64 TLK# 64 MCSP respectively 64 boosted protease inhibitor 64 evaluating T DM1 64 APTIVUS r 64 HGS# 64 etanercept Enbrel 64 telomerase therapeutic 64 EURIDIS 64 SCH # 64 Budesonide foam crofelemer 64 Xanafide 64 EOquin TM phase 64 Crofelemer budesonide foam 64 Ocrelizumab 64 NATRECOR R 64 Alemtuzumab 64 melphalan prednisone 64 Fibrillex TM 64 KRN# 64 riociguat 64 Survival Benefit 64 Amgen Neulasta R 64 plus DOXIL 64 Genasense ® 64 hematological cancers notably 64 Vascular Disrupting Agent 64 diarrhea predominant irritable 64 QUADRAMET R 64 Pegylated interferon 64 Bortezomib 64 BENICAR HCT 64 neovascular diseases 64 nucleotide analogue 64 Allovectin 7 64 ELOXATIN 64 Silodosin 64 Soriatane 64 CCX# 64 Ribavirin causes 64 Deforolimus 64 Elitek 64 measurable tumor regressions 64 Bucindolol 64 Kit CD# positive 64 BENLYSTA ® 64 HCV NS5B polymerase 64 IMiDs R 64 PSN# [002] 64 administered concomitantly 64 talactoferrin 64 Soft Tissue Sarcoma 64 visilizumab 64 Adjuvant chemotherapy 64 weekly subcutaneous injections 64 oral FTY# 64 Copegus ribavirin 64 Ceflatonin 64 Liprotamase 64 intravenous belinostat 64 REVLIMID ® 64 evaluating REVLIMID 64 Initiates Phase II 64 Interferon beta 1a 64 Topline Results 64 CCR5 antagonist 64 Zytiga 64 heavily pretreated 64 Luteinizing Hormone Releasing Hormone 64 enzastaurin 64 Myelofibrosis 64 Epidermal Growth Factor Receptor 64 evaluating Prochymal 64 unresectable 64 alefacept 64 immunoconjugate 64 Metabolic Efficiency 64 agalsidase alfa 64 irinotecan chemotherapy 64 receiving INTRON 64 investigational oral hepatitis C 64 RANK Ligand inhibitor 64 CYP#A# CYP#D# 64 ancrod 64 Zenvia ™ 64 bortezomib Velcade 64 Pivotal Trial 64 Stage IIIB IV 64 Curaxin CBLC# 64 IAP inhibitors 64 chemotherapy gemcitabine 64 CDK cyclin dependent 64 humanized anti 64 leukemia ALL 64 Neulasta R 64 pegylated interferons 64 RoACTEMRA 64 EGFr humanized monoclonal antibody 64 ganetespib 64 Seliciclib CYC# 64 non alcoholic steatohepatitis 64 Dementia Related Psychosis 64 tumor xenograft models 64 Double Blind Placebo 64 resistant ovarian cancer 64 carboplatin paclitaxel 64 Zevalin R Ibritumomab 64 Abiraterone acetate 64 treat benign prostatic 64 Completes Enrollment 64 Investigational Compound 64 Zoraxel 64 taxane refractory 64 TRACON Pharmaceuticals 64 androgen deprivation 64 Golimumab 64 AVN# Phase 64 Sorafenib 64 tiuxetan 64 sorafenib Nexavar R 64 anticancer compound 64 adjuvant radiation 64 metformin HCl 64 mCRC 64 BENLYSTA belimumab 64 DAVANAT 64 myelofibrosis polycythemia vera 64 EGFR expressing metastatic colorectal 64 mCRPC 64 folinic acid FA 64 rNAPc2 64 Peg IFN 64 lesinurad 64 HuMax EGFr 64 Multiple Myeloma MM 64 acetonide FA 64 metformin sulfonylurea 64 Benign Prostatic Hyperplasia 64 Immunotherapeutic 64 IMiDs ® compound 64 nitazoxanide 64 RCW Breast Cancer 64 completely resected 64 AGILECT R 64 Solorel TM 64 Abiraterone Acetate 64 Serostim ® 64 Mg Uk 64 IV Busulfex 64 Phase IIa trial 64 acyclovir Lauriad R 64 IV NSCLC 64 Omnitarg 64 non porcine pancreatic 64 peginterferon alpha 2a 64 generation NNRTI 64 Receives Orphan Drug Designation 64 autologous cellular immunotherapy 64 Malignant Melanoma 64 terlipressin 64 Onalta ™ 64 Phase Ib clinical 64 Amplimexon 64 APEX PD 64 curative resection 64 thymalfasin 64 interferon alfa 2b 64 HCV RESPOND 2 64 ErbB2 positive 64 Ridaforolimus 64 non squamous NSCLC 64 Cloretazine R VNP#M 64 metastatic malignant melanoma 64 Initiates Phase III 64 anti amnesic 64 HuLuc# 64 unfractionated heparin UFH 64 Tavocept 64 Myocet 64 Phase Ib IIa 64 Diabetic Macular Edema DME 64 Improved Survival 64 Panzem NCD 64 CALGB # [002] 64 triggers apoptosis programmed 64 PRN FDA Approves 64 Gemcitabine 64 metastatic CRC 64 budesonide foam 64 ALN TTR 64 Phase IIb trials 64 previously untreated follicular 64 medically inoperable 64 candidate AQ4N 64 Vicinium TM 64 Initiate Clinical Trial 64 somatropin Kuvan R 64 Tocilizumab 64 Drug Candidate 64 RSR# 64 ANCHOR trial 64 oncolytic virus therapies 64 biliary tract cancer 64 LibiGel ® 64 Anticancer Activity 64 Relapsing Multiple Sclerosis 64 stage IIIb 64 REYATAZ r 64 PROSTVAC TM 64 transthyretin TTR mediated amyloidosis 64 ELND# 64 ATL# [001] 64 CLARITY TIMI 64 Randomized Double Blind 64 ATACAND 64 Dapagliflozin 64 anti EGFR antibody 64 CRLX# 64 pediatric acute lymphoblastic 64 liposomal doxorubicin 64 FOLFOX chemotherapy 64 randomized controlled Phase 64 moderate renal impairment 64 HoFH 64 secondary hyperparathyroidism 64 Dose Escalation 64 achieved CCyR 64 fluoropyrimidine oxaliplatin 64 ribavirin therapy 64 azilsartan medoxomil 64 ovarian lung 64 Fondaparinux 64 metabolic disorders Saizen R 64 Mylan Receives Approval 64 recurrent malignant glioma 64 Patients Receiving 64 ARCOXIA 64 ocrelizumab 64 PI3K/Akt pathway inhibitor 64 Prospective Randomized 64 hormone refractory 64 PXD# 64 Pertuzumab 64 Zolinza 64 Bazedoxifene 64 Hodgkin lymphoma HL 64 VICTOR E3 64 corticosteroid dexamethasone 64 CINTREDEKIN BESUDOTOX 64 personalized cellular immunotherapy 64 huN# DM1 64 See CLINICAL PHARMACOLOGY 64 agonistic human 64 chronic lymphocytic leukemia CLL 64 nilotinib Tasigna 64 Palifosfamide 64 ATRA IV 64 dexamethasone Decadron 64 KRAS mutation 64 achieved ACR# 64 prostate cancer mHRPC 64 RhuDex ® 64 whose tumors overexpress 64 histone deacetylase HDAC inhibitor 64 proteasome inhibitor 64 Azedra 64 Naive Patients 63 Relapsing Remitting Multiple Sclerosis 63 retinal vein occlusion induced 63 panitumumab Vectibix 63 morphometric vertebral fractures 63 mGluR5 negative 63 pain palliation 63 Preclinical Data 63 Pegasys plus Copegus 63 ribavirin Copegus ® 63 Combination therapy 63 cytotoxic therapy 63 Troxatyl 63 acute peripheral arterial 63 Anastrozole